What's in Astellas Pharma Europe B.V.'s pipeline?

Astellas Pharma Europe B.V. has 29 drugs in our index: 2 marketed, 0 filed, 6 in Phase 3, 9 in Phase 2, 12 in Phase 1.

Which companies overlap with Astellas Pharma Europe B.V.'s portfolio?

Top competitors by shared drug class: Astellas Pharma Inc, AmMax Bio, Inc., Aronora, Inc., Astellas Pharma Global Development, Inc., Addpharma Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/astellas-pharma-europe-b-v.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Astellas Pharma Europe B.V. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Astellas Pharma Europe B.V. pipeline: 2 marketed, 0 filed, 6 Phase 3, 9 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 6 Phase 3 9 Phase 2 12 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Locobase® REPAIR	Locobase® REPAIR	marketed	Emollient/skin barrier repair product		Dermatology
bismuth tripotassium dicitrate	bismuth tripotassium dicitrate	marketed
Fidaxomicin tablets	Fidaxomicin tablets	phase 3	Macrocyclic antibiotic	Bacterial RNA polymerase (C. difficile)	Infectious Disease
Vancomycin oral liquid	Vancomycin oral liquid	phase 3	glycopeptide antibiotic	D-alanyl-D-alanine terminus of cell wall precursors	Infectious Diseases
Placebo to match solifenacin succinate	Placebo to match solifenacin succinate	phase 3			Urology
Vancomycin capsules	Vancomycin capsules	phase 3	glycopeptide antibiotic	D-alanyl-D-alanine terminus of cell wall precursors	Infectious Diseases
Placebo to match mirabegron	Placebo to match mirabegron	phase 3			Urology
Fidaxomicin oral suspension	Fidaxomicin oral suspension	phase 3	Macrocyclic antibiotic	Bacterial RNA polymerase (C. difficile)	Infectious Disease

Therapeutic area mix

Immunology · 4
Infectious Disease · 2
Infectious Diseases · 2
Urology · 2
Dermatology · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Astellas Pharma Inc · 3 shared drug classes
AmMax Bio, Inc. · 1 shared drug class
Aronora, Inc. · 1 shared drug class
Astellas Pharma Global Development, Inc. · 1 shared drug class
Addpharma Inc. · 1 shared drug class
AstraZeneca · 1 shared drug class
Axikin Pharmaceuticals, Inc. · 1 shared drug class
ADARx Pharmaceuticals, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Astellas Pharma Europe B.V.:

Cite this brief

Drug Landscape (2026). Astellas Pharma Europe B.V. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/astellas-pharma-europe-b-v. Accessed 2026-05-17.